AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37339332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC)
Number of subjects: 51
Study 37339332 — intervention group
Group type: COMPARATOR
Intervention: Immediate release hydrocortisone (IR-HC)
Number of subjects: 51
Study 37339332 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study 37339334 — intervention group
Group type: EXPERIMENTAL
Intervention: HPT-JT-related parathyroid tumors
Number of subjects: 68
Study 37339334 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine tumors
Number of subjects: 68
Study 37339334 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney tumors
Number of subjects: 68
Study 37339334 — intervention group
Group type: EXPERIMENTAL
Intervention: Parafibromin staining of parathyroid tumors
Number of subjects: 68
Study 37339334 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-sequencing
Number of subjects: 68
Study 37339342 — intervention group
Group type: EXPERIMENTAL
Intervention: Impart APN
Number of subjects: 55
Study 37339342 — intervention group
Group type: COMPARATOR
Intervention: Self-tell notification (treatment as usual)
Number of subjects: 55
Study 37339352 — intervention group
Group type: COMPARATOR
Intervention: Light Vibrational Forces (LVF)
Number of subjects: 1027
Study 37339352 — intervention group
Group type: COMPARATOR
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 1027
Study 37339352 — intervention group
Group type: COMPARATOR
Intervention: Light Emitting Diode (LED)
Number of subjects: 1027
Study 37339360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 37339360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37339363 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Weight Loss and Lifestyle Intervention
Number of subjects: 0
Study 37339363 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37339390 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Number of subjects: 21
Study 37339390 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Number of subjects: 21
Study 37339396 — intervention group
Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 5 mg (LEM5)
Number of subjects: 280
Study 37339396 — intervention group
Group type: EXPERIMENTAL
Intervention: LEMBOREXANT 10 mg (LEM10)
Number of subjects: 280
Study 37339396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 280
Study 37339441 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine Transdermal System
Number of subjects: 0
Study 37339483 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAG-M/sorafenib
Number of subjects: 81
Study 37339483 — intervention group
Group type: COMPARATOR
Intervention: CLAG-M
Number of subjects: 81
Study 37339586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat (Vorinostat 100 mg twice a day for DL1 and 200 mg twice a day for DL2, administered orally from days 1 to 5 and 8 to 12; Pembrolizumab 200 mg IV every 3 weeks)
Number of subjects: 32
Study 37339586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat in patients refractory to prior PD-1 blockade (n=18)
Number of subjects: 32
Study 37339586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus vorinostat
Number of subjects: 32
Study 37339820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention based on Plan-Do-Study-Act cycles
Number of subjects: 10
Study 37339820 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 10
Study 37339817 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI-nf training to increase amygdala responses during positive memory recall
Number of subjects: 38
Study 37339817 — intervention group
Group type: COMPARATOR
Intervention: Parietal responses during positive autobiographical memory recall (control group)
Number of subjects: 38
Study 37339979 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX vaccine with low-dose cyclophosphamide (Arm A)
Number of subjects: 40
Study 37339979 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX vaccine with anti-PD-1 antibody nivolumab (Arm B)
Number of subjects: 40
Study 37339979 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX vaccine with nivolumab and anti-CD137 agonist antibody urelumab (Arm C)
Number of subjects: 40
Study 37339979 — intervention group
Group type: COMPARATOR
Intervention: GVAX+nivolumab+urelumab (Arm C)
Number of subjects: 40
Study 37339979 — intervention group
Group type: COMPARATOR
Intervention: GVAX (Arm A)
Number of subjects: 40
Study 37339979 — intervention group
Group type: COMPARATOR
Intervention: GVAX+nivolumab (Arm B)
Number of subjects: 40
Study 37340107 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy (DG)
Number of subjects: 211
Study 37340107 — intervention group
Group type: COMPARATOR
Intervention: Total Gastrectomy (TG)
Number of subjects: 211
Study 37340170 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session intervention including safety plans with mobile augmentation
Number of subjects: 53
Study 37340170 — intervention group
Group type: COMPARATOR
Intervention: 4-session intervention including safety plans without mobile augmentation
Number of subjects: 53
Study 37340213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted Therapy (DAT)
Number of subjects: 71
Study 37340213 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 71
Study 37340264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge arms (various combinations of brief messages based on behavioral science)
Number of subjects: 27540
Study 37340264 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 27540
Study 37340268 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical scribes in cardiology
Number of subjects: 18
Study 37340268 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical scribes in orthopedics
Number of subjects: 18
Study 37340268 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical scribes in both cardiology and orthopedics
Number of subjects: 18
Study 37340300 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (phone health education session on day 1)
Number of subjects: 536
Study 37340300 — intervention group
Group type: COMPARATOR
Intervention: Control (no health education)
Number of subjects: 536
Study 37340306 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement + PFMT
Number of subjects: 32
Study 37340306 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PFMT
Number of subjects: 32
Study 37340318 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive markers of mitochondrial capacity (citrate synthase activity, mitochondrial DNA copy number, TOMM20, VDAC, protein content for complex I-V of the oxidative phosphorylation system)
Number of subjects: 19
Study 37340318 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive assessments of mitochondrial capacity (PCr recovery postexercise)
Number of subjects: 19
Study 37340369 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy using surgical gloves
Number of subjects: 104
Study 37340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-OS with r-FSH
Number of subjects: 120
Study 37340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-OS with u-HMG
Number of subjects: 120
Study 37340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-OS with r-FSH
Number of subjects: 120
Study 37340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-OS with u-HMG
Number of subjects: 120
Study 37340371 — intervention group
Group type: COMPARATOR
Intervention: All groups (including controls)
Number of subjects: 120
Study 37340397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chemotherapy (Ara-C) administered at home by parents
Number of subjects: 0
Study 37340397 — intervention group
Group type: EXPERIMENTAL
Intervention: Home chemotherapy intervention
Number of subjects: 0
Study 37340439 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Number of subjects: 65
Study 37340439 — intervention group
Group type: COMPARATOR
Intervention: CBT-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Number of subjects: 65
Study 37340439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MI and CBT treatments
Number of subjects: 65
Study 37340492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech-CBT intervention
Number of subjects: 70
Study 37340664 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary infection in seronegative girls
Number of subjects: 363
Study 37340664 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in anti-CMV antibody in seropositive girls
Number of subjects: 363
Study 37340664 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV DNA shedding in urine
Number of subjects: 363
Study 37340664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CMV infection during follow-up
Number of subjects: 363
Study 37340664 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfection or reactivation rates
Number of subjects: 363
Study 37340832 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab with dexamethasone
Number of subjects: 0
Study 37341028 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU and the App (App Group)
Number of subjects: 73
Study 37341028 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU and the App + a commercial discount (App + Discount Group)
Number of subjects: 73
Study 37341028 — intervention group
Group type: COMPARATOR
Intervention: TAU (Control Group)
Number of subjects: 73
Study 37341164 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-613
Number of subjects: 20
Study 37341164 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical cohort)
Number of subjects: 20
Study 37341189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulins (ATG)
Number of subjects: 1413
Study 37341243 — intervention group
Group type: EXPERIMENTAL
Intervention: IDP-126 gel (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Number of subjects: 1020
Study 37341243 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1020
Study 37341243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad gels (1 of the 3 dyad gels, phase 2 only)
Number of subjects: 1020
Study 37341351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold haemostasis during tonsillectomy
Number of subjects: 0
Study 37341351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot diathermia during tonsillectomy
Number of subjects: 0
Study 37341530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle-mediated therapeutic approaches to the myocardium
Number of subjects: 0
Study 37341530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoscience and nanoparticle-mediated approaches
Number of subjects: 0
Study 37341530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle-mediated tissue-targeted therapies
Number of subjects: 0
Study 37341586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 300
Study 37341586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 37341778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus Lenalidomide and Dexamethasone (IRd)
Number of subjects: 45
Study 37341915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 100 IU/kg daily
Number of subjects: 0
Study 37341915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 125 IU/kg
Number of subjects: 0
Study 37341915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose of 150 IU/kg
Number of subjects: 0
Study 37341915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose escalation to 150 IU/kg
Number of subjects: 0
Study 37341915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcinonacog alfa (DalcA) at a dose escalation to 200 IU/kg
Number of subjects: 0
Study 37341961 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD; 75/75/150 mg)
Number of subjects: 198
Study 37341961 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD; 75/150/300 mg)
Number of subjects: 198
Study 37341961 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 198
Study 37341961 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (0.8 mg/kg)
Number of subjects: 198
Study 37341961 — intervention group
Group type: COMPARATOR
Intervention: Adult patients receiving secukinumab
Number of subjects: 198
Study 37342018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfascial (TF) mesh fixation
Number of subjects: 325
Study 37342018 — intervention group
Group type: COMPARATOR
Intervention: No mesh fixation (sham incisions)
Number of subjects: 325
Study 37342036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67
Study 37342036 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene (control)
Number of subjects: 67
Study 37342040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition Cathodal Direct Current Stimulation (HD C-tDCS) at 1 mA for 20 minutes and 2 mA for 20 minutes
Number of subjects: 10
Study 37342040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition Cathodal Direct Current Stimulation (HD C-tDCS)
Number of subjects: 10
Study 37342040 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 37342080 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent (internet-based intervention)
Number of subjects: 881
Study 37342080 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent (internet-based intervention) with 100% dosage
Number of subjects: 881
Study 37342080 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 881
Study 37342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention SOPHIE (8-week duration)
Number of subjects: 222
Study 37342086 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 222
Study 37342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention SOPHIE
Number of subjects: 222
Study 37342189 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 + RT + TMZ
Number of subjects: 16
Study 37342313 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 48
Study 37342313 — intervention group
Group type: COMPARATOR
Intervention: MVA
Number of subjects: 48
Study 37342359 — intervention group
Group type: COMPARATOR
Intervention: Surgical mask (ASTM Level 3 disposable surgical mask)
Number of subjects: 119
Study 37342495 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure monitoring during otorhinolaryngologic surgery
Number of subjects: 199
Study 37342775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week auto-CPAP treatment
Number of subjects: 32
Study 37342775 — intervention group
Group type: COMPARATOR
Intervention: Non-CPAP treatment
Number of subjects: 32
Study 37342862 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium hearing aids
Number of subjects: 190
Study 37342862 — intervention group
Group type: COMPARATOR
Intervention: Basic hearing aids
Number of subjects: 190
Study 37342923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 795
Study 37342923 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted PI
Number of subjects: 795
Study 37342922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-tacrolimus-mycophenolate mofetil (experimental prophylaxis)
Number of subjects: 431
Study 37342922 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus-methotrexate (standard prophylaxis)
Number of subjects: 431
Study 37343084 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis and ambulatory fraction collector for measuring tissue adrenal steroids
Number of subjects: 214
Study 37343084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical and computational methods for quantifying interindividual variability
Number of subjects: 214
Study 37343084 — intervention group
Group type: COMPARATOR
Intervention: Comparison of tissue measurements against plasma measurements
Number of subjects: 214
Study 37343145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 20 mg
Number of subjects: 145
Study 37343145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 37343335 — intervention group
Group type: EXPERIMENTAL
Intervention: PUMAS (mindfulness-based intervention)
Number of subjects: 12
Study 37343576 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Plasma-Lyte 148)
Number of subjects: 808
Study 37343576 — intervention group
Group type: COMPARATOR
Intervention: Saline (0·9% sodium chloride)
Number of subjects: 808
Study 37343623 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab treatment (Beovu, Novartis)
Number of subjects: 505
Study 37343625 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-μg bimatoprost implant
Number of subjects: 31
Study 37343695 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of postpartum hemorrhage
Number of subjects: 16382
Study 37343695 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal transfusion history
Number of subjects: 16382
Study 37343695 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oxytocin during labor
Number of subjects: 16382
Study 37343695 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 16382
Study 37343695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction
Number of subjects: 16382
Study 37343745 — intervention group
Group type: EXPERIMENTAL
Intervention: FN-EDB assay in IPF patients
Number of subjects: 133
Study 37343745 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 133
Study 37344061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lutein and zeaxanthin supplementation for three months
Number of subjects: 21
Study 37344080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/day)
Number of subjects: 44
Study 37344080 — intervention group
Group type: COMPARATOR
Intervention: Control (avoid all nuts)
Number of subjects: 44
Study 37344091 — intervention group
Group type: EXPERIMENTAL
Intervention: High avocado allotment (14 avocados per week)
Number of subjects: 90
Study 37344091 — intervention group
Group type: COMPARATOR
Intervention: Low avocado allotment (3 avocados per week)
Number of subjects: 90
Study 37344262 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 694
Study 37344262 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 694
Study 37344265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster dose (5 × 10^10 viral particles)
Number of subjects: 0
Study 37344337 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pain neuroscience education (PPNE)
Number of subjects: 120
Study 37344337 — intervention group
Group type: COMPARATOR
Intervention: Traditional biomedical education (PBE)
Number of subjects: 120
Study 37344340 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 765
Study 37344340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 765
Study 37344340 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 765
Study 37344474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) plus weekly paclitaxel (80 mg/m2)
Number of subjects: 0
Study 37344474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) plus flat-dose capecitabine
Number of subjects: 0
Study 37344582 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Assistant for Retinoblastoma Monitoring (DLA-RB) algorithm
Number of subjects: 103
Study 37344582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ophthalmologists and DLA-RB
Number of subjects: 103
Study 37344582 — intervention group
Group type: EXPERIMENTAL
Intervention: DLA-RB-based diagnosis mode
Number of subjects: 103
Study 37344582 — intervention group
Group type: EXPERIMENTAL
Intervention: DLA-RB
Number of subjects: 103
Study 37344582 — intervention group
Group type: EXPERIMENTAL
Intervention: DLA-RB-based screening and surveillance
Number of subjects: 103
Study 37344745 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS scan
Number of subjects: 198
Study 37344751 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PUR1900 (itraconazole) at doses up to 40 mg per day
Number of subjects: 0
Study 37344751 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (5 mg) co-administered with inhaled PUR1900
Number of subjects: 0
Study 37344778 — intervention group
Group type: EXPERIMENTAL
Intervention: GuG-Auf intervention (12 sessions)
Number of subjects: 135
Study 37344778 — intervention group
Group type: EXPERIMENTAL
Intervention: GuG-Auf intervention
Number of subjects: 135
Study 37344778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study 37344778 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 135
Study 37344780 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic nipple-sparing mastectomy (RNSM)
Number of subjects: 2000
Study 37344789 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Discontinuation (OD)
Number of subjects: 196
Study 37344789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden Discontinuation (HD)
Number of subjects: 196
Study 37344789 — intervention group
Group type: COMPARATOR
Intervention: Open Continuation (OC)
Number of subjects: 196
Study 37344789 — intervention group
Group type: COMPARATOR
Intervention: Hidden Continuation (HC)
Number of subjects: 196
Study 37344789 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 196
Study 37344801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration of 250 ml of crystalloid fluid
Number of subjects: 69